Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Emtage
Peter Emtage, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090041809 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS - Immunostimulatory agents, including nucleic acids having one or more than one locked nucleic acid (LNA) nucleosides are provided. The nucleic acids may further comprise CpG motifs. The nucleic acids may be double stranded, and may comprise dsRNA. | 02-12-2009 |
| 20110038888 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER - An adjuvant composition comprising polyIC and a cationic polymer; the cationic polymer comprising from about 100 to about 500 amino acid residues, wherein the mass:mass ratio of the polyIC:cationic polymer is from about 4:1.5 to about 4:3 is described. | 02-17-2011 |
| 20110142873 | BIOACTIVE PURIFIED HSPE7 COMPOSITIONS - A method of treating or preventing a condition related to an HPV infection is provided. The method comprises administering to a subject a composition comprising a purified Hsp65-E7 fusion protein (HspE7) admixed with an immune stimulant selected from the group consisting of CpG, a TLR3 agonist such as PolyI:C, PolyICLC, mono-phosphoryl-lipid A (MPL), MPL-trehalose 6,6′-dimycolate (MPL-TDM), and anti-CD40. A composition comprising HspE7 and one or more than one of CpG, a TLR3 agonist such as PolyI:C, PolyICLC, MPL, MPL-TDM, and anti-CD40, and method of reducing a tumor or virus development in a mammal or subject in need thereof by using the composition are also provided. | 06-16-2011 |
Peter C.r. Emtage, Edmonton CA
| Patent application number | Description | Published |
|---|---|---|
| 20080200388 | Stem cell factor-like proteins and uses thereof - The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa. | 08-21-2008 |
| 20090118176 | Stem Cell Factor-Like Protein Scfa1 and Uses Thereof - Methods for stimulating epithelial cell proliferation and for treating oral and gastrointestinal disorders are described. The methods use compositions comprising stem cell factor-like protein A1 (SCFA1) polypeptides and polynucleotides. | 05-07-2009 |
| 20100278800 | Stem cell factor-like proteins and uses thereof - The invention relates to pharmaceutical compositions comprising gastrointestinal proliferative factor SCFA2, SCFA4 or SCFA4v polynucleotides and polypeptides. The invention further relates to the therapeutic use of SCFA2, SCFA4 or SCFA4v to prevent or treat conditions or disorders associated with the degeneration of the epithelial mucosa. | 11-04-2010 |
Peter C.r. Emtage, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090053136 | Methods of Therapy and Diagnosis Using Immunotargeting of CD84Hy1-expressing Cells - Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1 Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1 protein-expressing cells are described. | 02-26-2009 |
| 20090081209 | METHODS OF THERAPY AND DIAGNOSIS USING TARGETING OF CELLS THAT EXPRESS KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR-LIKE PROTEINS - Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described. | 03-26-2009 |